Dr Ahlgen speaks with ecancertv at ASCO 2016 about the results of SPCG12, a randomised phase III trial assessing patient survival following radical prostatectomy with docetaxel.
Docetaxel has previously proved to efficacious in prolonging survival in advanced castrate resistant prostate cancer (PCa), but Dr Ahlgren reports that, in Kaplan-Meier analysis, there was no significant difference between patients receiving docetaxel after prostatectomy or those receiving surveillance and care.
He highlights that docetaxel as a monotherapy seems to generate a more rapid biochemical progression in a subgroup of patients, and that further analysis of this subgroup is warranted.
ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.